PropertyValue
?:abstract
  • We complement the discussion by Brindisi et al. [1] on the management of allergic rhinitis in children amid novel coronavirus disease 2019 (COVID‐19) pandemic. Brindisi et al. [1] presented a well‐reasoned discussion on the use of intranasal corticosteroids and allergen immunotherapy in children with allergic rhinitis amid COVID‐19 pandemic where they recommend continuation of the former while withholding of the latter upon risk‐benefit assessment.
?:creator
?:doi
  • 10.1111/apa.15491
?:doi
?:journal
  • Acta_Paediatr
?:license
  • no-cc
?:pdf_json_files
  • document_parses/pdf_json/00e50fae243dc0b1f1efdc7c91e58d831fa8d96a.json
?:pmcid
?:pmid
?:pmid
  • 32686128.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Medline; PMC
?:title
  • Montelukast in children with allergic rhinitis amid COVID‐19 pandemic
?:type
?:year
  • 2020-07-19

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/92sa6pl1>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/92sa6pl1>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all